176 related articles for article (PubMed ID: 1799186)
1. Clinicopathological findings of bucillamine-induced nephrotic syndrome in patients with rheumatoid arthritis.
Yoshida A; Morozumi K; Suganuma T; Sugito K; Ikeda M; Oikawa T; Fujinami T; Takeda A; Koyama K
Am J Nephrol; 1991; 11(4):284-8. PubMed ID: 1799186
[TBL] [Abstract][Full Text] [Related]
2. [Bucillamine-associated membranous nephropathy in a patient with rheumatoid arthritis].
Kawano M; Nomura H; Iwainaka Y; Nakashima A; Koni I; Tofuku Y; Takeda R
Nihon Jinzo Gakkai Shi; 1990 Jul; 32(7):817-21. PubMed ID: 2273598
[TBL] [Abstract][Full Text] [Related]
3. [Clinicopathological evaluation and treatment of bucillamine induced membranous nephropathy].
Kikuchi M; Saeki T; Ito S; In H; Saito T; Ueno M; Sato T; Suzuki S; Nakano M; Ozawa T
Ryumachi; 1993 Jun; 33(3):215-22. PubMed ID: 8346463
[TBL] [Abstract][Full Text] [Related]
4. Bucillamine (a new therapeutic agent for rheumatoid arthritis) induced nephrotic syndrome: a report of two cases and review of the literature.
Isozaki T; Kimura M; Ikegaya N; Arai T; Fujigaki Y; Hishida A; Kaneko E
Clin Investig; 1992 Nov; 70(11):1036-42. PubMed ID: 1472834
[TBL] [Abstract][Full Text] [Related]
5. Bucillamine induces membranous glomerulonephritis.
Nagahama K; Matsushita H; Hara M; Ubara Y; Hara S; Yamada A
Am J Kidney Dis; 2002 Apr; 39(4):706-12. PubMed ID: 11920335
[TBL] [Abstract][Full Text] [Related]
6. Clinical course of bucillamine-induced nephropathy in patients with rheumatoid arthritis.
Obayashi M; Uzu T; Harada T; Yamato M; Takahara K; Yamauchi A
Clin Exp Nephrol; 2003 Dec; 7(4):275-8. PubMed ID: 14712356
[TBL] [Abstract][Full Text] [Related]
7. [Membranous glomerulonephritis probably related to bucillamine therapy in two patients with rheumatoid arthritis].
Baba N; Nomura T; Sakemi T; Uchida M; Watanabe T
Nihon Jinzo Gakkai Shi; 1991 Jun; 33(6):629-34. PubMed ID: 1920943
[TBL] [Abstract][Full Text] [Related]
8. Membranous glomerulonephritis in patients with rheumatoid arthritis.
Yoshida A; Morozumi K; Takeda A; Koyama K; Oikawa T
Clin Ther; 1994; 16(6):1000-6. PubMed ID: 7697679
[TBL] [Abstract][Full Text] [Related]
9. A case of rapidly progressive glomerulonephritis associated with bucillamine-treated rheumatoid arthritis.
Yoshida A; Morozumi K; Takeda A; Koyama K; Oikawa T; Fujinami T
Am J Kidney Dis; 1992 Oct; 20(4):411-3. PubMed ID: 1415212
[No Abstract] [Full Text] [Related]
10. [A case of progressive systemic sclerosis with Sjögren's syndrome complicated by nephrotic syndrome caused by bucillamine].
Ogawa N; Itoh M; Sudo Y; Endo S; Ohashi H; Okugawa T; Furuya R; Hishida A
Ryumachi; 1990 Oct; 30(5):362-6, 308; discussion 366-8. PubMed ID: 2084858
[TBL] [Abstract][Full Text] [Related]
11. Outcome and treatment of bucillamine-induced nephropathy.
Hoshino J; Ubara Y; Hara S; Suwabe T; Sawa N; Tagami T; Katori H; Takemoto F; Hara S; Takaichi K
Nephron Clin Pract; 2006; 104(1):c15-9. PubMed ID: 16685139
[TBL] [Abstract][Full Text] [Related]
12. Bucillamine-induced nephropathy in a child with juvenile rheumatoid arthritis and Kartagener's syndrome.
Kawasaki Y; Suzuki J; Sike T; Isome M; Nozawa R; Suzuki S; Suyama K; Suzuki H
Pediatr Int; 2000 Jun; 42(3):316-8. PubMed ID: 10881595
[No Abstract] [Full Text] [Related]
13. Immunopharmacological evaluation of bucillamine in rheumatoid arthritis.
Matsuno H; Kitano T; Matsushita I; Tsuji H; Ochiai H
Drugs Exp Clin Res; 1993; 19(5):205-11. PubMed ID: 8174492
[TBL] [Abstract][Full Text] [Related]
14. [A case of rheumatoid arthritis developing pemphigus-like skin lesion during treatment with bucillamine].
Amasaki Y; Sagawa A; Atsumi T; Jodo S; Nakabayashi T; Watanabe I; Mukai M; Fujisaku A; Nakagawa S; Kobayashi H
Ryumachi; 1991 Oct; 31(5):528-34; discussion 531-3. PubMed ID: 1837388
[TBL] [Abstract][Full Text] [Related]
15. [A case of drug-induced interstitial pneumonitis in rheumatoid arthritis treated with bucillamine].
Matsushima H; Takayanagi N; Sakamoto T; Motegi M; Ubukata M; Yanagisawa T; Sugita Y; Kanazawa M; Kawabata Y
Nihon Kokyuki Gakkai Zasshi; 2001 Jan; 39(1):55-9. PubMed ID: 11296388
[TBL] [Abstract][Full Text] [Related]
16. [Drug induced nephrotic syndrome].
Ohno I
Nihon Rinsho; 2004 Oct; 62(10):1919-24. PubMed ID: 15500140
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathological study of nephropathy in patients with rheumatoid arthritis].
Yoshida A; Morozumi K; Suganuma T; Aoki J; Sugito K; Koyama K; Oikawa T; Fujinimi T; Matsumoto Y
Ryumachi; 1991 Feb; 31(1):14-21. PubMed ID: 1677490
[TBL] [Abstract][Full Text] [Related]
18. Hyperplasia of Lymphoid Follicles and Lymphangiectasia in the Parietal Pleura in Bucillamine-induced Yellow Nail Syndrome.
Hase I; Kurasawa K; Takizawa H; Yamaguchi B; Sakuma H; Ishii Y
Intern Med; 2018 Jul; 57(13):1887-1892. PubMed ID: 29434155
[TBL] [Abstract][Full Text] [Related]
19. [A case of pulmonary infiltration with eosinophilia (PIE) syndrome induced by bucillamine treatment of rheumatoid arthritis].
Kishimoto N; Fujii K
Nihon Kokyuki Gakkai Zasshi; 2002 Apr; 40(4):321-5. PubMed ID: 12096503
[TBL] [Abstract][Full Text] [Related]
20. Membranous nephropathy caused by rheumatoid arthritis.
Iida A; Wada Y; Hayashi J; Tachibana S; Inaba T; Iyoda M; Honda K; Shibata T
CEN Case Rep; 2019 Nov; 8(4):233-238. PubMed ID: 31037495
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
